These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 35086853)

  • 61. [Comparison of microdilution and disk diffusion methods for the detection of fluconazole and voriconazole susceptibility against clinical Candida glabrata isolates and determination of changing susceptibility with new CLSI breakpoints].
    Hazırolan G; Sarıbaş Z; Arıkan Akdağlı S
    Mikrobiyol Bul; 2016 Jul; 50(3):428-37. PubMed ID: 27525398
    [TBL] [Abstract][Full Text] [Related]  

  • 62. In vitro effects of ciprofloxacin, levofloxacin and moxifloxacin on Mycobacterium tuberculosis isolates.
    Yılmaz FF; Eraç B; Ermertcan Ş; Çavuşoğlu C; Biçmen C; Aktoğu Özkan S; Hoşgör Limoncu M
    Tuberk Toraks; 2018 Mar; 66(1):32-36. PubMed ID: 30020039
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Results from the Survey of Antibiotic Resistance (SOAR) 2014-16 in Greece.
    Torumkuney D; Papaparaskevas J; Morrissey I
    J Antimicrob Chemother; 2018 Apr; 73(suppl_5):v36-v42. PubMed ID: 29659884
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Antimicrobial susceptibility testing of Neisseria gonorrhoeae isolates in Pakistan by Etest compared to Calibrated Dichotomous Sensitivity and Clinical Laboratory Standards Institute disc diffusion techniques.
    Mal PB; Jabeen K; Farooqi J; Unemo M; Khan E
    BMC Microbiol; 2016 Oct; 16(1):236. PubMed ID: 27724873
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Antimicrobial resistance in urinary tract pathogens in Canada from 2007 to 2009: CANWARD surveillance study.
    Karlowsky JA; Lagacé-Wiens PR; Simner PJ; DeCorby MR; Adam HJ; Walkty A; Hoban DJ; Zhanel GG
    Antimicrob Agents Chemother; 2011 Jul; 55(7):3169-75. PubMed ID: 21537027
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Results from the Survey of Antibiotic Resistance (SOAR) 2011-13 in Ukraine.
    Feshchenko Y; Dzyublik A; Pertseva T; Bratus E; Dzyublik Y; Gladka G; Morrissey I; Torumkuney D
    J Antimicrob Chemother; 2016 May; 71 Suppl 1(Suppl 1):i63-9. PubMed ID: 27048583
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Association between fluoroquinolone utilization rates and susceptibilities of gram-negative bacilli: Results from an 8-year intervention by an antibiotic stewardship program in an inner-city United States hospital.
    Zeana C; Palmieri FE; Gupta V; Ye G; Lao P; Yu K; Kang KS; Schiller L; Purswani M
    Sci Prog; 2021; 104(2):368504211011876. PubMed ID: 33908291
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Cephalexin susceptibility breakpoint for veterinary isolates: Clinical Laboratory Standards Institute revision.
    Papich MG; Lindeman C
    J Vet Diagn Invest; 2018 Jan; 30(1):113-120. PubMed ID: 29145786
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Six-year susceptibility trends and effect of revised Clinical Laboratory Standards Institute breakpoints on ciprofloxacin susceptibility reporting in typhoidal
    Saksena R; Nayyar C; Manchanda V
    Indian J Med Microbiol; 2016; 34(4):520-525. PubMed ID: 27934835
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Mechanisms accounting for fluoroquinolone resistance in Escherichia coli clinical isolates.
    Morgan-Linnell SK; Becnel Boyd L; Steffen D; Zechiedrich L
    Antimicrob Agents Chemother; 2009 Jan; 53(1):235-41. PubMed ID: 18838592
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Fluoroquinolone resistance mechanisms in urinary tract pathogenic Escherichia coli isolated during rapidly increasing fluoroquinolone consumption in a low-use country.
    Christiansen N; Nielsen L; Jakobsen L; Stegger M; Hansen LH; Frimodt-Møller N
    Microb Drug Resist; 2011 Sep; 17(3):395-406. PubMed ID: 21668371
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Development of in vitro resistance to fluoroquinolones in Pseudomonas aeruginosa.
    Zhao L; Wang S; Li X; He X; Jian L
    Antimicrob Resist Infect Control; 2020 Aug; 9(1):124. PubMed ID: 32758289
    [TBL] [Abstract][Full Text] [Related]  

  • 73. In vitro synergy studies using aztreonam and fluoroquinolone combinations against six species of Gram-negative bacilli.
    Critchley IA; Sahm DF; Kelly LJ; Karlowsky JA
    Chemotherapy; 2003 May; 49(1-2):44-8. PubMed ID: 12714810
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Characterization of fluoroquinolone-resistant beta-hemolytic Streptococcus spp. isolated in North America and Europe including the first report of fluoroquinolone-resistant Streptococcus dysgalactiae subspecies equisimilis: report from the SENTRY Antimicrobial Surveillance Program (1997-2004).
    Biedenbach DJ; Toleman MA; Walsh TR; Jones RN
    Diagn Microbiol Infect Dis; 2006 Jun; 55(2):119-27. PubMed ID: 16530373
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Results from the Survey of Antibiotic Resistance (SOAR) 2016-17 in Ukraine: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints.
    Torumkuney D; Bratus E; Yuvko O; Pertseva T; Morrissey I
    J Antimicrob Chemother; 2020 Apr; 75(Suppl 1):i100-i111. PubMed ID: 32337596
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Correlation of Vitek 2 and Agar dilution for levofloxacin susceptibility testing and clinical outcomes of Enterobacterales bacteremia with 2019 CLSI breakpoints.
    Huang HY; Chang YT; Lu PL; Yang TY; Wang YL; Chen TC; Wu JH; Lin SY
    Diagn Microbiol Infect Dis; 2022 Dec; 104(4):115799. PubMed ID: 36215940
    [TBL] [Abstract][Full Text] [Related]  

  • 77. In vitro Activity of Sitafloxacin and Other Antibiotics against Bacterial Isolates from HRH Princess Maha Chakri Sirindhorn Medical Center, Srinakharinwirot University and Samitivej Sukhumvit Hospital.
    Tantisiriwat W; Linasmita P
    J Med Assoc Thai; 2017 Apr; 100(4):469-78. PubMed ID: 29912484
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Assessment of the comparability of CLSI, EUCAST and Stokes antimicrobial susceptibility profiles for Escherichia coli uropathogenic isolates.
    O'Halloran C; Walsh N; O'Grady MC; Barry L; Hooton C; Corcoran GD; Lucey B
    Br J Biomed Sci; 2018 Jan; 75(1):24-29. PubMed ID: 29210602
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Impact of revised CLSI breakpoints for susceptibility to third-generation cephalosporins and carbapenems among Enterobacteriaceae isolates in the Asia-Pacific region: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART), 2002-2010.
    Huang CC; Chen YS; Toh HS; Lee YL; Liu YM; Ho CM; Lu PL; Liu CE; Chen YH; Wang JH; Tang HJ; Yu KW; Liu YC; Chuang YC; Xu Y; Ni Y; Ko WC; Hsueh PR
    Int J Antimicrob Agents; 2012 Jun; 40 Suppl():S4-10. PubMed ID: 22749058
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Burden of Fluoroquinolone Resistance in Clinical Isolates of
    Deku JG; Duedu KO; Ativi E; Kpene GE; Feglo PK
    Ethiop J Health Sci; 2022 Jan; 32(1):93-102. PubMed ID: 35250221
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.